Floretyrosine F 18 (Pixclara)
Optional dilutionFull monograph review pending
U.S. label preparation
Pixclara · Optional dilution
- Preparation
- The PET radiopharmaceutical may be diluted with 0.9% sodium chloride. Confirm activity and dose volume before injection.
- Administration and handling
- Use radiation shielding and follow the product's calibration, expiry and imaging instructions.
Product and source details
Telix Pharmaceuticals (US) Inc. · NDA218592
Product NDC: 74725-338
SPL effective 2026-10-07 | SPL version 4. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.